This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A handful of patience is worth more than a bushel of brains
—Dutch proverb
Controversy exists concerning almost every aspect of the diagnosis and management of multiple sclerosis (MS), the most common nontraumatic cause of neurologic disability in young adults. Although authoritative guidelines for diagnosis, such as those of the McDonald Committee, are available, a high rate of false positive attribution of MS has been observed in clinical practice.1 On the other hand, data from the North American Research Committee on Multiple Sclerosis registry demonstrate that the ascertainment time (from first symptom to diagnosis) is currently very brief, indicating that false negative attribution of MS is rare or transient.2 Currently, overdiagnosis in suspected MS is the most common diagnostic error and has been ascribed to uncritical reliance on MRI and hasty workup.1,3
Management of MS is controversial, both in terms of the general role of disease-modifying treatment (DMT) and the merits of specific DMTs. A recent “Controversies in Neurology” in the Archives of Neurology featured opposing reviews by MS specialists either favoring or questioning universal institution of DMT once MS or a MS-like clinically isolated syndrome is diagnosed.4,5 Experts on both sides of this dispute agree with the authoritative Cochrane reviewers …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
Impact of multiple sclerosis relapses on progression diminishes with time
A reassessment of the plateauing relationship between T2 lesion load and disability in MS
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis